Navigation Links
Antineoplastic agents associated with thyroid dysfunction
Date:10/18/2011

Antineoplastic agents such as immunotherapies and targeted therapies that specifically target signaling pathways in cancer cells are associated with thyroid dysfunction in 20%-50% of cancer patients taking them, which can adversely affect patients' quality of life, according to a study published Oct. 18 in the Journal of the National Cancer Institute.

Over the past two decades, novel antineoplastic agents have been introduced that inhibit specific cellular processes to limit cancer cell growth. Some of these agents cause thyroid dysfunction, which physicians often overlook because of the complexity of the clinical picture in cancer patients. The symptoms of thyroid dysfunction, such as fatigue, weakness, depression, memory loss, and cardiovascular effects can be wrongly attributed to the primary disease. If under-diagnosed, thyroid dysfunction can adversely affect a patient's quality of life.

To understand the thyroid-related side effects of antineoplastic agents, their frequency, and underlying mechanisms, Ole-Petter Riksfjord Hamnvik, M.D., of the Division of Endocrinology, Diabetes, and Hypertension at Brigham and Women's Hospital in Boston, and colleagues reviewed articles on thyroid dysfunction in cancer patients. The researchers found that there are no known strategies to prevent thyroid disease in patients receiving these new antineoplastic agents, and that possible preventative measures may be more toxic than the thyroid disease itself. They also say that screening for thyroid disease is likely beneficial, but note that there were no screening recommendations for asymptomatic patients in the literature they reviewed. However, in this review, the authors provide their own recommendations for patients based on the pattern of abnormalities with each agent, in addition to recommending the monitoring of thyroid function tests in clinical trials of antineoplastic agents.

The researchers also recommend several paths of research that should be pursued, namely knowledge of the biological effects of the antineoplastic agents on the thyroid, so they can identify possible preventative strategies and improve the proposed screening strategies. They also recommend performing large randomized clinical trials of screening and treatment of thyroid disease to evaluate the improvements in patient quality of life and fatigue as well as to evaluate the unanticipated effects of cancer outcomes.

The researchers write, "Treatment for thyroid diseases is safe and likely to enhance patient quality of life, as well as potentially allow effective treatments for the underlying cancer to continue."

They note however, that there are many levels of uncertainty and that most of the data are derived from case reports or case series, small prospective studies, or laboratory-based studies. They recommend close monitoring of patients receiving these antineoplastic agents. "This may allow early recognition and treatment of thyroid disease, allowing continued treatment of the underlying cancer, as well as improving the quality of life of the patient."


'/>"/>

Contact: Zack Rathner
jncimedia@oxfordjournals.org
301-841-1286
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. Professional Insurance Agents to Hold 2010 Federal Legislative Summit March 17-18
2. Long Term Care Insurance Leader Seeks 320 New Agents in 2010, Following Strong 2009 Growth
3. Professional Insurance Agents Name Rep. Charlie Melancon 2010 Legislator of the Year
4. Health Insurance Agents Work with Zane Benefits to Offer New Solutions amid Health Care Reform
5. Mayo-led research team develop agents that keep insulin working longer
6. Study provides molecular rationale for combining targeted agents to treat breast cancer
7. VCU Massey first to combine targeted agents to kill multiple myeloma cells
8. Improved protocols for contrast agents eliminates new cases of nephrogenic systemic fibrosis
9. Turning agents of disease into tools for health and better living
10. New anti-cancer agents show promise for treating aggressive breast cancers
11. Imaging agents offer new view of inflammation, cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , ... February 05, 2016 , ... ... devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through ... poised to once again host, Swirl, A Wine Tasting Event at the La ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... PROSHRED franchises from across the country gathered at the La Valencia Hotel in ... performers. PROSHRED Chicago was named the year’s most outstanding franchise, walking away ...
(Date:2/5/2016)... ... February 05, 2016 , ... Regular gym users know the routine: each ... longer to access the treadmills. It’s a predictable trend. After the excesses of November ... get in shape by joining gyms, starting new walking or running routines, or signing ...
(Date:2/5/2016)... ... ... Boar’s Head Brand®, one of the nation’s leading providers of premium delicatessen ... stress out of your party preparation – follow these easy, yet delicious recipes with ... game. , “The key to hosting a successful game-day party is creating a flavorful ...
(Date:2/5/2016)... ... , ... At its annual meeting held last week, the American Parkinson Disease ... of Directors. Mr. McDermott succeeds former APDA Chairman, Fred Greene. , "We are pleased ... APDA President and CEO. “Pat has tirelessly served APDA since 2001 when he was ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... Feb. 4, 2016   Bernstein Liebhard LLP today ... the United States District Court for the District of ... "Class") consisting of all persons or entities who purchased common ... INSY ) from March 3, 2015 through January 25, ... of its officers with violations of the Securities Exchange Act ...
(Date:2/4/2016)... Feb. 4, 2016 Summary Breast cancer, ... and the most common cancer in women worldwide, accounting ... exceedingly prevalent. The number of women diagnosed with breast ... the number of deaths has declined due to earlier ... has been revolutionized in the past four decades, especially ...
(Date:2/4/2016)... Feb. 4, 2016 Mettler-Toledo International Inc. (NYSE: ... 2015.  Provided below are the highlights: , ... compared with the prior year.  Reported sales decreased 3% ... quarter. , Net earnings per diluted share as ... prior- year period.  Adjusted EPS was $4.65, an increase ...
Breaking Medicine Technology: